ImmunityBio Inc (NASDAQ: IBRX) on Tuesday, plunged -7.96% from the previous trading day, before settling in for the closing price of $2.26. Within the past 52 weeks, IBRX’s price has moved between $1.83 and $5.88.
Annual sales at Healthcare sector company grew by 2.39% over the past five years. The company achieved an average annual earnings per share of 21.18%. With a float of $98.33 million, this company’s outstanding shares have now reached $915.63 million.
ImmunityBio Inc (IBRX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ImmunityBio Inc is 89.60%, while institutional ownership is 13.28%.
ImmunityBio Inc (IBRX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.12 earnings per share (EPS) for the period topping the consensus outlook (set at -0.18) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 43.55% during the next five years compared to 2.39% growth over the previous five years of trading.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
ImmunityBio Inc (IBRX) is currently performing well based on its current performance indicators. A quick ratio of 3.98 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.49, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of ImmunityBio Inc (IBRX)
ImmunityBio Inc (NASDAQ: IBRX) saw its 5-day average volume 8.62 million, a positive change from its year-to-date volume of 8.32 million. As of the previous 9 days, the stock’s Stochastic %D was 10.36%.
During the past 100 days, ImmunityBio Inc’s (IBRX) raw stochastic average was set at 0.85%, which indicates a significant decrease from 1.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.12 in the past 14 days, which was lower than the 0.15 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.49, while its 200-day Moving Average is $2.73. Nevertheless, the first resistance level for the watch stands at $2.18 in the near term. At $2.29, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.34. If the price goes on to break the first support level at $2.02, it is likely to go to the next support level at $1.97. Assuming the price breaks the second support level, the third support level stands at $1.86.
ImmunityBio Inc (NASDAQ: IBRX) Key Stats
Market capitalization of the company is 2.14 billion based on 984,965K outstanding shares. Right now, sales total 14,750 K and income totals -413,560 K. The company made 26,430 K in profit during its latest quarter, and -92,560 K in sales during its previous quarter.
